Clinical trials: BMI
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and…
- Trial name
- MEASURE (NCT07639684)
- Testing
- ESG with OverStitch
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Obesity, Overweight
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- ACCESS II (NCT06703021)
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity, Overweight
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
This study in China is open to adults who are at least 18 years old who are living with overweight or obesity. People with a body mass index (BMI) of 28 kg/m^2 or higher or 24 kg/m^2 or higher with at least 1 weight related…
- Trial name
- NCT06214741
- Testing
- survodutide
- Where
- 28 sites in China
- Volunteers
- 307 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
The purpose of this study is to observe clinical effectiveness of canagliflozin by mean haemoglobin A1c (HbA1C) and body weight changes from baseline to 12 weeks in Indian type 2 diabetes participants.
- Trial name
- NCT03604224
- Testing
- Canagliflozin 300 mg
- Where
- 3 sites in India
- Volunteers
- 178 people
- Sponsor
- Johnson & Johnson Private Limited
Skin Aging, Weight Loss
Effect of Revival Soy on Weight Loss and Skin, Hair, and Nails in Premenopausal Women
The purpose of this study is to determine if dietary consumption of Revival Soy can improve the appearance of the skin, hair, and finger nails and support weight loss in overweight, premenopausal women.
- Trial name
- NCT00352157
- Testing
- Revival Soy Dietary Supplement
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Physicians Pharmaceuticals, Inc.
Sleep Apnea, Obstructive
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of IBI362 in subjects with moderate-to-severe obstructive sleep apnea (OSA) and a body mass index…
- Conditions
- Sleep Apnea, Obstructive, Obesity
- Trial name
- NCT06931028
- Testing
- IBI362
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with…
- Trial name
- BMT-801 (NCT06565611)
- Testing
- bremelanotide, tirzepatide
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Palatin Technologies, Inc
Osteoarthritis
A Phase I, Prospective, Randomized, Open-label, Active-Controlled Clinical Trial for Safety Evaluation of Intra-articular Injection of RegenoGel-SP for the Treatment of Moderate to Severe Osteoarthritis
This is a Phase I, prospective, active-controlled, randomized, open-label, clinical trial designed to assess the safety and tolerability of single intra-articular injection of RegenoGel-SP for the treatment of OA.
- Trial name
- NCT02188771
- Testing
- intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- ProCore Ltd.
Elevated Body Mass Index
Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index
A 12-week study to assess LIK066 effect on body weight in diabetics, prediabetics and normoglycemic patients with elevated body mass index (BMI)
- Trial name
- NCT02470403
- Testing
- LIK066
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00303602
- Testing
- Sublingual orally disintegrating olanzapine (SODO), Oral olanzapine
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 149 people
- Sponsor
- Eli Lilly and Company
Obesity
Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066
The purpose of this study was to determine if LIK066 taken with a meal containing low carbohydrate is associated with less diarrhea compared to a high carbohydrate meal and to assess the potential effects of supplements such as…
- Trial name
- NCT03198767
- Testing
- LIK066, Carbohydrate 50%, Carbohydrate 25%
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Overweight or Obesity
Pylorus Distensibility Measurement
The present study aims at characterizing the pylorus functionality in overweight and obese patients (BMI 27-40) using a systematic measurement approach by using an impedance planimetry technology.
- Trial name
- NCT06908551
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- BariaTek Medical
Obesity
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with…
- Trial name
- GZBF (NCT07467447)
- Testing
- Retatrutide (LY3437943), Standardized diet and physical activity counseling throughout the study.
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Hudson Biotech
Obese Adults
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.
- Trial name
- NCT07838740
- Testing
- VK2735 Drug
- Where
- 2 sites in United States
- Volunteers
- 270 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity & Overweight
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations
This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with co-morbidities or related diseases.
- Trial name
- NCT07338214
- Testing
- Petrelintide
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Healthy Volunteer
Calorie Restriction Intervention Induces Enterotype-associated BMI Loss in Nonobese Individuals
Calorie restriction (CR), which has the potential effect on weight loss and blood amino acids, has been demonstrated to associate with gut microbiota in humans, especially in obese individuals.
- Trial name
- CRDI (NCT04044118)
- Testing
- Low Calorie Diet
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- BGI-Shenzhen
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Overweight, Obesity
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
This study is open to Chinese adults aged 18 to 60 with overweight or obesity. People can join the study if they have a Body Mass Index from 24 to 40.0 kg/m2.
- Trial name
- NCT06492135
- Testing
- survodutide
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Prostate Cancer, Obesity
PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
The reports on relationship of obesity and biochemical or clinical recurrence of prostate cancer are controversial. Several reports have shown that obesity is associated with increased risk of biochemical or clinical failure…
- Trial name
- PROTECT-Z (NCT01020604)
- Where
- 34 sites in Hungary
- Volunteers
- 1,376 people
- Sponsor
- AstraZeneca
Obesity, Cardiovascular Diseases
Evaluation of Body Composition Improvement With Visceral Adiposity-Focused Anti-Obesity Telehealth Program
A retrospective review of body composition changes in patients who participate in a 9-week non-invasive intensive health care provider supervised weight loss program as an overall cohort and in sub-cohorts of interest.
- Conditions
- Obesity, Cardiovascular Diseases, Metabolic Syndrome, Metabolic Disease
- Trial name
- NCT05219240
- Testing
- 20Lighter Program
- Where
- 2 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- 20Lighter